Latest ArticlesTo investigate the effect of neoadjuvant chemotherapy combined with mannitol enema on R0 resection rate of locally advanced rectal cancer (LARC).
A total of 90 patients with LARC admitted to the first affiliated hospital of Hebei north hospital from June 2015 to June 2019 were selected and divided into control group (neoadjuvant chemotherapy+radical operation) and the intervention group (neoadjuvant chemotherapy+mannitol enema+radical operation). The relevant indicators before treatment, before operation and after operation were observed and recorded, and statistical analysis was performed.
The R0 resection rate of the intervention group was significantly higher than that of the control group, while the operative time and intraoperative blood loss were significantly lower than those of the control group, and the differences were statistically significant (P<0.05). The rate of anastomotic bleeding and tumor recurrence in the intervention group were significantly lower than those in the control group, and the differences were statistically significant (P<0.05).
Neoadjuvant chemotherapy combined with mannitol enema can increase the R0 resection rate of LARC, decrease the operation time, reduce the postoperative complications and tumor recurrence, which is beneficial to the prognosis of patients and worthy of clinical promotion.
To explore the clinical effects of Yangxin Shengmai granules in the treatment of ischemic heart failure (IHF) caused by Qi deficiency and blood stasis, and its effect on cardiac function, serum S100 calcium-binding protein A8/A9 complex (S100A8/A9), nuclear factor (NF)-κB, receptor of advanced glycation end-product (RAGE) and high mobility group protein (HMG) B1 levels.
A total of 102 patients with IHF admitted to the department of cardiology of our hospital from March 2017 to March 2019 were selected as the study objects and divided into control group (conventional western medicine treatment) and observation group (conventional western medicine treatment+Yangxin Shengmai granules), with 51 cases in each group. The course of treatment was 3 months. Clinical efficacy and drug safety of the two groups were observed, and traditional Chinese medicine (TCM) syndrome score, 6 minute walking test (6MWT), Minnesota living with heart failure questionnaire (MLHF-Q) score, cardiac output (CO), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), heart rate variability (HRV) parameters, plasma brain natriuretic peptide (BNP), serum S100A8/A9, NF-κB, RAGE and HMGB1 levels were compared between the two groups.
The total effective rate of observation group was higher than that of control group (94.12% vs 80.39%, P<0.05). The TCM syndrome score and MLHF-Q score of the observation group were lower than those of the control group, and the 6MWT score was higher than that of the control group (P<0.05). The LVEF, CO and HRV parameters of the observation group were higher than those of the control group, and the levels of LVESD, LVEDD and plasma BNP were lower than those of the control group (P<0.05). Serum levels of S100A8/A9, NF-κB, RAGE and HMGB1 in observation group were lower than those in control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (7.84% vs 9.80%, P>0.05).
Yangxin Shengmai granules has a significant effect on IHF of Qi deficiency and blood stasis, which can effectively improve clinical symptoms, cardiac function and quality of life, delay ventricular remodeling process to a certain extent, and improve serum levels of S100A8/A9, NF-κB, RAGE and HMGB1.
To investigate the effect of febuxostat combined with hemodialysis in the treatment of chronic kidney disease (CKD) and its effect on fibroblast growth factor (FGF) 23 and bone metabolism.
A total of 105 patients with CKD who treated at the department of nephrology in our hospital from February 2020 to February 2021 were selected and divided into experimental group (n=53, hemodialysis+febuxostat) and control group (n=52, hemodialysis) by random number table method. The clinical efficacy, serum FGF23, serum uric acid, serum calcium, blood phosphorus, parathyroid hormone (PTH), serum creatinine (Scr), blood urea nitrogen (BUN) and occurrence of adverse reactions were compared between the two groups.
After treatment, there was a statistically significant difference in the total effective rate between the control group and the experimental group (51.92% vs 81.13%, P<0.05), but no statistically significant difference in the incidence of adverse reactions (9.43% vs 19.23%, P>0.05). The levels of serum FGF23, blood uric acid, blood phosphorus, PTH, Scr and BUN in both groups were decreased with time, and the experimental group were lower than those in the control group, the differences were statistically significant (P<0.05). The serum calcium level of both groups increased with time, and the experimental group was higher than that in the control group, the difference was statistically significant (P<0.05). Serum FGF23 and blood uric acid were positively correlated with blood phosphorus, PTH, Scr and BUN (P<0.05), and negatively correlated with blood calcium (P<0.05).
Febuxostat combined with hemodialysis has a significant effect in patients with CKD, which can effectively improve serum FGF23 and bone metabolism, with good safety.
Roxadustat is a new hypoxia-inducible factor prolyl hydroxylase inhibitor. It could effectively alleviate anemia symptoms and increase the level of hemoglobin in dialysis and non-dialysis patients with chronic kidney disease anemia, with no inferior or even superior efficacy to erythropoietin stimulating agents. Roxadustat has been marketed in China, Japan and some many European countries, whereas its safety issues such as adverse drug reactions and drug interactions deserve attention. This paper reviewed the research progress and clinical application of roxadustat, so as to provide reference for its further development and rational use.
To compare the cost and effectiveness of fractional flow reserve (FFR) combined with coronary angiography (CAG) versus CAG alone in guiding the diagnosis and treatment of coronary atherosclerotic heart disease from the perspective of China's medical and health system.
The evaluation model of health economics (short-term decision tree plus long-term Markov model) was constructed. The length of each cycle of the model was 1 year, and the simulation period was 10 years. The model was used to compare the difference in the degree of coronary stenosis between FFR combined with CAG group (FFR group) and CAG group. The difference in the composition of the treatment methods of the two groups were analyzed and the cost-effectiveness was measured.
The overall cost of FFR group was 109 434 Yuan, and the corresponding effect was 7.75 quality adjusted life years (QALYs). The overall cost of CAG group was 120 722 Yuan, and the corresponding effect was 7.65 QALYs. Compared with CAG group, the incremental cost-effectiveness ratio of FFR group was -112 460 Yuan/QALYs.
FFR group is more cost-effective than CAG group. The advantage of FFR group comes from the accurate diagnosis of coronary functional lesions to help doctors accurately determine the degree of stenosis and treatment methods, avoid unnecessary percutaneous coronary intervention surgery and stent implantation, improve the quality of life of patients, and reduce the medical cost of complications.
In recent years, the number of rare dise ase drugs included in the national medical insurance negotiation list has been increased, and the landing of rare disease drugs in National Negotiation Drugs is the key to evaluate the effect of the policy. Based on the online drug procurement data of medical institutions in Hubei province from January 2018 to December 2022, this article conducted a study on rare disease drugs that had been negotiated four times between 2017 and 2021. Defined daily doses (DDDs), defined daily dose cost and procurement amount were selected to compare before and after the policy, and catastrophic health expenditure indicators were used to evaluate the affordability of rare disease drugs. The analysis revealed that among the 21 negotiated rare disease drugs, 5 drugs were not procured by medical institutions in Hubei province from 2017 - 2021. Compared with 2018, the DDDs and procurement amount decreased in 2019, but the DDDs and amount of negotiated rare disease drugs increased year by year from 2020 to 2022. Before reimbursement by medical insurance, there were 14 and 15 drugs with annual treatment costs exceeding catastrophic health expenditures for urban and rural residents, respectively. After reimbursement by employee medical insurance, there were 7 and 10 drugs with annual treatment costs exceeding catastrophic health expenditures for urban and rural residents, respectively. There were 10 and 13 drugs after reimbursement by residents' medical insurance, respectively. Therefore, it is suggested that the government should take lead improving the multi-party co-payment for rare disease drugs and achieve classified management for the extremely poor population, so as to consolidate the guarantee of people's livelihood.
Traditional Chinese medicine (TCM) cosmetology is a discipline that uses TCM characteristic therapy under the guidance of TCM theory and Chinese aesthetic theory to correct or cover up diseases that damage beauty, so as to maintain the beauty of human form and body. In recent years, with the improvement of people's living standards, the demand for medical cosmetology is growing. TCM cosmetology has been widely used in modern cosmetics field such as whitening, freckle removal, anti-wrinkle, removing scar and weight loss because of its internal and external health, safety, economy, convenient and other advantages. This article took the modern application of TCM cosmetology as the main line, summarized the methods of TCM cosmetology and the existing clinical and basic research, in order to provide reference for the clinical application and further research of TCM cosmetology, and promote the construction and development of TCM cosmetology.
Treatment for hyperpigmented disorders often takes a long time to work and has poor patient compliance. Hyperpigmented skin diseases can be effectively treated by using a variety of lasers based on the principle of selective photothermolysis. Choosing the most appropriate type of laser depends on various factors, such as the melanin chromophore and its specific lesion location in the skin. This article reviewed the laser treatment on several hyperpigmentation disorders, such as nevoid lentigo, café-au-lait macules, Becker's nevus, intradermal nevus, nevus of Ota, melasma and post-inflammatory pigmentation etc, and compares the advantages of various lasers on the basis of published studies.